July 31, 2024
FDA Criticizes Brittany Mahomes’ Paid Instagram Post for Kaléo’s Auvi-Q
FDA, Brittany Mahomes, Kaléo, Auvi-Q, misleading advertisement, social media regulation, pharmaceutical marketing
Ideaya Secures $400M Deal for Biocytogen Bispecific ADC, Aiming to Enhance Drug Combinations
Ideaya Biosciences, Biocytogen, bispecific ADC, drug combinations, $400M deal, biobucks, DNA damage repair molecules
GSK Abandons Phase 2 HPV Vaccine Due to Lack of Best-in-Class Potential
GSK, HPV vaccine, phase 2, best-in-class potential, vaccine development
FibroGen Lays Off 75% of US Staff After Cancer Drug Fails in Two Phase III Trials
FibroGen, cancer drug, layoffs, Phase III trials, pamrevlumab, oncology, pancreatic cancer, chemotherapy, anaemia therapy, roxadustat, Astellas, AstraZeneca
Novo’s GLP-1 Liraglutide May Protect Brain from Alzheimer’s, New Study Finds
GLP-1, Liraglutide, Alzheimer’s Disease, Brain Protection, Cognitive Decline, Novo Nordisk
Biosecure Lawmakers Target China Studies in New Regulatory Push
Biosecure Act, China studies, clinical trials, biopharma, U.S.-China relations, drug production, national security, pharmaceutical supply chain
FibroGen to Shrink US Workforce by 75% Following More Late-Stage Fails
FibroGen, workforce reduction, pamrevlumab, clinical trials, biotech layoffs, pancreatic cancer drug
Biopharma Layoff Tracker 2024: FibroGen, Pfizer, Cue, and More Cut Staff
Biopharma layoffs, FibroGen, Pfizer, Cue, Anokion, biotech industry, job cuts, restructuring initiatives
BioNTech-Regeneron vs. Moderna-Merck.Cancer Vaccine and PD-1 Inhibitor Combinations.
, BioNTech, Regeneron, Moderna, Merck, Cancer Vaccine, PD-1 Inhibitor, mRNA Technology, Melanoma, Immunotherapy, Clinical Trials,